Feature | April 08, 2011| Dave Fornell

Stenting Equal to CABG in PRECOMBAT Trial

Sirolimus-eluting stents were shown to equal coronary artery bypass surgery (CABG), but questions remain about long-term durability

The rates of death, heart attack and stroke were equal for patients in the PRECOMBAT trial, regardless if they received a stent or CABG.

A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to coronary artery bypass surgery (CABG) in patients with unprotected left main coronary artery disease. Rates of death, heart attack, stroke and ischemia-driven target vessel revascularization (TVR) were all equal, according to research presented this week at the American College of Cardiology (ACC) Scientific Session in New Orleans.

“PCI [percutaneous coronary intervention] seems the same as CABG, however, the results were wide, so it is not a clinical mandate in the results,” said Seung-Jung Park, M.D., Ph.D., lead study author and professor of medicine at the University of Ulsan College of Medicine in Seoul, South Korea.

The trial follows decades of questioning among cardiovascular specialists about which procedure – CABG or angioplasty – yields better outcomes. While angioplasty is less invasive and requires a shorter recovery time, it is also associated with a greater need for repeat procedures and a reduced ability to fully revascularize patients with multivessel disease. Although numerous trials have been conducted comparing the two procedures, a lack of randomized clinical trials has left the question open to debate.

“In spite of higher revascularization after angioplasty, it can be a potential alternative if the two treatments have a similar risk of hard endpoints, such as death, heart attack or stroke,” Park said. “At the time this study was initiated, there was great enthusiasm about the outcomes of angioplasty, and as a result, off-label use rapidly spread without enough evidence. Therefore, initiation of a randomized study was urgent.”

Study Details

For the study, the researchers randomized 600 patients to receive either CABG (n = 300) or angioplasty with the sirolimus-eluting Cypher stent (manufactured by Cordis; n = 300). After the procedure, clinical followup was conducted at 30 days and six, nine and 12 months; angiographic followup was conducted from eight to 10 months for the angioplasty cohort.

The study’s primary outcome measure was a composite of major adverse cardiac or cerebrovascular events (MACCE) at 12 months that included: death from any cause, heart attack, stroke and ischemia-driven TVR.

The researchers found that angioplasty was not inferior to CABG for the primary outcome measure, with MACCE rates of 8.7 percent and 6.7 percent, respectively (p = 0.001; HR 1.29, 95 percent CI, 0.72 – 2.32). The rates of MACCE at 24 months were also comparable between the two groups, at 12.2 percent for angioplasty and 8.1 percent for CABG. A different composite of death, heart attack and stroke (which was used as a safety indicator) also showed similar outcomes at 24 months, at 4.4 percent for the angioplasty cohort and 4.7 percent in the CABG cohort (p = 0.83).

The research team did find a significant difference, however, in the rates of ischemia-driven TVR at 24 months. Specifically, 9 percent of patients in the angioplasty group experienced this individual outcome, compared with 4.2 percent in the CABG group (p = 0.022).

“Our study endpoints included safety and efficacy outcomes. The incidences of death, heart attack and stroke – which are indicators of safety and have a significant impact on mortality – were comparable,” Park said. “Although angioplasty did have a higher risk of TVR, this efficacy endpoint does not have a direct association with mortality and thus has a less significant implication than the safety outcomes. Therefore, we can conclude that angioplasty can be a feasible alternative to CABG surgery.”

In the angioplasty arm, intravascular ultrasound (IVUS) was used in 91 percent of patients to evaluate lesions and for vessel sizing. In patients with bifurcation lesions, a single-stent technique was employed in 87 percent of the cases.

In the surgical arm, left internal mammary arteries (LIMA) grafts were used in 233 of the 300 CABG patients.

Surgery May Still Be Best Option for Long-Term Outcomes

After the trial presentation, panelists compared this trial to the SYNTAX trial, which was a comparison of the Taxus stent vs. CABG. That trial slightly favored CABG. Three-year outcomes data from SYNTAX appear to show surgery has better durability without the need for repeat revascularization, which was required in a higher percentage of PCI patients, said panelist Bernard Gersh, MB, Ch.B. D.Phil., FRCP, FACC, Mayo Clinic College of Medicine, Division of Cardiovascular Diseases at Mayo Clinic.

"There does seem to be a divergence in MACCE rates as time goes on, especially in patients with two- and three-vessel disease,” said panelist Steven Bolling, M.D., a cardiac surgeon at the University of Michigan. He said data from the past three years seem to show CABG has better durability than PCI.

Panelist Gregg Stone, M.D., director of cardiovascular research and education, Cardiovascular Research Foundation, said PRECOMBAT had an improvement over SYNTAX in that IVUS was used in the majority of cases to help decide if stenting was necessary and for more accurate stent sizing to avoid malapposition. This may have led to better outcomes for PCI in this trial compared to SYNTAX.

The PRECOMBAT study was supported by funds from the Cardiovascular Research Foundation (Seoul), Cordis and the Health 21 Research and Development Project (Ministry of Health and Welfare, South Korea). Park had no disclosures.

This study was published this week in the New England Journal of Medicine (NEJM).

Related Content

smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
Teleflex, AVA 2016 Congress, Association for Vascular Access
News | Vascular Access| September 20, 2016
September 20, 2016 — Teleflex Inc.
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Overlay Init